{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05067140",
            "orgStudyIdInfo": {
                "id": "ARV-766-mCRPC-101"
            },
            "organization": {
                "fullName": "Arvinas Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer",
            "officialTitle": "A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-arv-given-by-mouth-in-men-with-metastatic-prostate-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-09-02",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-06-27",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-09-23",
            "studyFirstSubmitQcDate": "2021-10-04",
            "studyFirstPostDateStruct": {
                "date": "2021-10-05",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-04",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Arvinas Androgen Receptor, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth alone or in combination with abiraterone in men with metastatic prostate cancer."
        },
        "conditionsModule": {
            "conditions": [
                "Prostate Cancer Metastatic"
            ],
            "keywords": [
                "Metastatic Prostate Cancer",
                "Castrate-Resistant",
                "Prostate Cancer",
                "mCRPC adenocarcinoma of prostate",
                "Prostatic Neoplasms",
                "Genital Neoplasms, Male",
                "Urogenital Neoplasms",
                "Castrate-Sensitive",
                "mCSPC adenocarcinoma of prostate"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 220,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "ARV-766",
                    "type": "EXPERIMENTAL",
                    "description": "Oral tablets, once daily in 28 day cycles",
                    "interventionNames": [
                        "Drug: ARV-766 Part A&B"
                    ]
                },
                {
                    "label": "ARV-766 + Abiraterone",
                    "type": "EXPERIMENTAL",
                    "description": "Oral tablets, once daily in 28 day cycles",
                    "interventionNames": [
                        "Drug: ARV-766 + Abiraterone Part C&D"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ARV-766 Part A&B",
                    "description": "Part A: Daily oral dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.\n\nPart B: Oral tablet(s) once daily in 28 day cycles.",
                    "armGroupLabels": [
                        "ARV-766"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "ARV-766 + Abiraterone Part C&D",
                    "description": "Part C: Daily oral combination dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.\n\nPart D: Combination administered once daily in 28 day cycles.\n\nParts C\\&D: Participants will also receive concomitant corticosteroid and ADT therapy of investigator choice/patient preference",
                    "armGroupLabels": [
                        "ARV-766 + Abiraterone"
                    ],
                    "otherNames": [
                        "Corticosteroid and ADT"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part A: Incidence of Dose Limiting Toxicities of ARV-766",
                    "description": "First Cycle Dose limiting toxicities characterized by type, frequency, severity (as graded by NCI CTCAE v 5.0), timing, seriousness, and relationship to study drug",
                    "timeFrame": "28 Days"
                },
                {
                    "measure": "Part A: Number of Patients with Adverse Events as a measure of safety and tolerability of ARV-766",
                    "description": "Adverse events as characterized by type, frequency, severity (as graded by NCI CTCAE v 5.0), timing, seriousness, and relationship to study drug.",
                    "timeFrame": "28 Days"
                },
                {
                    "measure": "Part A: Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-766",
                    "description": "Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v 5.0), and timing.",
                    "timeFrame": "28 Days"
                },
                {
                    "measure": "Part B: To evaluate the clinical anti-tumor activity of ARV-766 in patients with mCRPC",
                    "description": "Evaluate PSA in patients with mCRPC in both dose groups",
                    "timeFrame": "12 Weeks"
                },
                {
                    "measure": "Part C: Incidence of Dose Limiting Toxicities of ARV-766 / abiraterone combination",
                    "description": "First Cycle Dose limiting toxicities characterized by type, frequency, severity (as graded by NCI CTCAE v 5.0), timing, seriousness, and relationship to study drug",
                    "timeFrame": "28 Days"
                },
                {
                    "measure": "Part C: Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-766 / abiraterone combination",
                    "description": "Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v 5.0), and timing.",
                    "timeFrame": "28 Days"
                },
                {
                    "measure": "Part C: Number of Patients with Adverse Events as a measure of safety and tolerability of ARV-766 / abiraterone combination",
                    "description": "Adverse events as characterized by type, frequency, severity (as graded by NCI CTCAE v 5.0), timing, seriousness, and relationship to study drug.",
                    "timeFrame": "28 Days"
                },
                {
                    "measure": "Part D: To evaluate the clinical anti-tumor activity of ARV-766 / abiraterone combination in patients with NHA-na\u00efve mPC",
                    "description": "Evaluate PSA in patients with NHA-na\u00efve mPC",
                    "timeFrame": "12 Weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nPart A,B,C and D:\n\n* Histological, pathological, or cytological confirmed diagnosis of adenocarcinoma of the prostate.\n* Ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone analog or inhibitor, or orchiectomy (surgical or medical castration).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\nPart A:\n\n* Progression on at least 2 prior approved systemic therapies for metastatic prostate cancer (at least one must be a second-generation androgen inhibitor, e.g., abiraterone, enzalutamide, darolutamide, apalutamide).\n* Progressive mCRPC\n\nPart B:\n\n* Participants must have received at least one but no more than three prior second generation anti-androgen agents (e.g., enzalutamide or abiraterone).\n* Participants must have received no more than two prior chemotherapy regimens.\n* Progressive mCRPC\n\nPart C \\& D:\n\n\u2022 Metastatic castration resistant or sensitive prostate cancer with radiographic evidence of metastatic disease\n\nExclusion Criteria:\n\nPart A and B:\n\n* Known symptomatic brain metastases requiring steroids (above physiologic replacement doses).\n* Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease, or previous gastric resection or lap band surgery.\n* Radiation therapy within 4 weeks of first dose of study drug or prior irradiation to \\>25% of the bone marrow.\n* Receipt of an investigational drug(s) within 4 weeks prior to anticipated first dose\n* Systemic anti-cancer therapy within 2 weeks of first dose of study drug (except agents to maintain castrate status). For bicalutamide, mitomycin C, or nitrosoureas the exclusion period must be 6 weeks and for abiraterone 4 weeks.\n\nPart C and D\n\n\u2022 Prior treatment with a second generation NHA",
            "healthyVolunteers": false,
            "sex": "MALE",
            "genderBased": true,
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Arvinas Androgen Receptor, Inc.",
                    "role": "CONTACT",
                    "phone": "475-345-3374",
                    "email": "clinicaltrialsARV-766@arvinas.com"
                }
            ],
            "locations": [
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Fresno",
                    "state": "California",
                    "zip": "93720",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.74773,
                        "lon": -119.77237
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "La Jolla",
                    "state": "California",
                    "zip": "92037",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.84727,
                        "lon": -117.2742
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Orange",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.78779,
                        "lon": -117.85311
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Santa Monica",
                    "state": "California",
                    "zip": "90404",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.01945,
                        "lon": -118.49119
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06510",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Washington",
                    "state": "District of Columbia",
                    "zip": "20007",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.89511,
                        "lon": -77.03637
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Lake Mary",
                    "state": "Florida",
                    "zip": "32746",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.75888,
                        "lon": -81.31784
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "New Orleans",
                    "state": "Louisiana",
                    "zip": "70112",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.95465,
                        "lon": -90.07507
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21204",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48201",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Buffalo",
                    "state": "New York",
                    "zip": "14203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.88645,
                        "lon": -78.87837
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19144",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15232",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Myrtle Beach",
                    "state": "South Carolina",
                    "zip": "29572",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.68906,
                        "lon": -78.88669
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Charlottesville",
                    "state": "Virginia",
                    "zip": "22908",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.02931,
                        "lon": -78.47668
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Madison",
                    "state": "Wisconsin",
                    "zip": "53705",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.07305,
                        "lon": -89.40123
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10018",
                    "name": "Hypersensitivity",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                }
            ]
        }
    },
    "hasResults": false
}